ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors

This study is currently recruiting participants.
Study NCT00602082.   Last updated on October 8, 2008.   Information provided by National Cancer Institute (NCI)

This Tabular View shows the required WHO registration data elements as marked by

Descriptive Information Fields
Brief Title  Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors
Official Title  A Randomised Phase II Study Comparing Capecitabine Plus Streptozocin With or Without Cisplatin Chemotherapy as Treatment for Unresectable or Metastatic Neuroendocrine Tumors
Brief Summary

RATIONALE: Drugs used in chemotherapy, such as capecitabine, streptozocin, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether giving capecitabine together with streptozocin is more effective with or without cisplatin in treating neuroendocrine tumors.

PURPOSE: This randomized phase II trial is studying giving capecitabine together with streptozocin to see how well it works compared with or without cisplatin in treating patients with unresectable or metastatic neuroendocrine tumors.

Detailed Description

OBJECTIVES:

Primary

  • To determine the objective response rate in patients with neuroendocrine tumors treated with capecitabine and streptozocin with or without cisplatin.

Secondary

  • To determine the overall response rate, including both objective and biochemical responses, to these regimens.
  • To determine the functional response to these regimens.
  • To determine the toxicity of these regimens.
  • To identify the optimal drug doses in each regimen to be recommended for a subsequent phase III trial.
  • To determine the progression-free and overall survival of patients receiving these regimens.
  • To determine the quality of life of these patients.
  • To determine molecular markers predictive of response to chemotherapy.

OUTLINE: This is a multicenter study. Patients are stratified according to site of origin (known vs unknown primary site), prior antitumor treatment, tumor function (functional vs nonfunctional), and study center. Patients are randomized to 1 of 2 treatment arms.

  • Arm I: Patients receive streptozocin IV over 2 hours on day 1 and oral capecitabine twice daily on days 1-21.
  • Arm II: Patients receive cisplatin IV over 2 hours on day 1 and streptozocin and capecitabine as in arm I.

In both treatment arms, treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.

Patients complete the EORTC QLQC30 questionnaire and EORTC QLQ-GI.NET21 module for quality-of-life assessment at baseline, every 9 weeks during treatment, and at 12 weeks post-treatment.

Tumor tissue is obtained at baseline and assessed for Ki67 and mitotic index. Novel tissue-specific transcription factors (e.g., CDX2) are also assessed. Blood samples are collected at baseline and 9 weeks and examined by DNA, RNA, and proteomic analysis.

After completion of study therapy, patients are followed every 12 weeks.

Study Phase Phase II
Study Type  Interventional
Study Design  Treatment, Randomized
Primary Outcome Measure  Objective response rate
Secondary Outcome Measure  Overall response rate
Functional response
Toxicity
Progression-free survival
Overall survival
Molecular markers predictive of response to chemotherapy
Quality of life
Condition  Gastrointestinal Carcinoid Tumor
Islet Cell Tumor
Intervention  Drug: capecitabine
Drug: cisplatin
Drug: streptozocin
Procedure: DNA analysis
Procedure: RNA analysis
Procedure: laboratory biomarker analysis
Procedure: protein analysis
Procedure: proteomic profiling
MEDLINE PMIDs
Links Clinical trial summary from the National Cancer Institute's PDQ® database This link exits the ClinicalTrials.gov site
Recruitment Information Fields
Recruitment Status  Recruiting
Enrollment  84
Start Date  August 2005
Completion Date
Eligibility Criteria 

DISEASE CHARACTERISTICS:

  • Histologically confirmed unresectable, advanced, and/or metastatic disease meeting one of the following types:

    • Gastroentero-neuroendocrine tumor of the foregut
    • Pancreatic neuroendocrine tumor
    • Neuroendocrine tumor of unknown primary
  • Measurable disease, defined as at least 1 lesion that can be accurately measured in at least 1 dimension (the longest diameter) ≥ 20 mm by conventional CT scanning or ≥ 10 mm by spiral CT scan or MRI
  • No bronchial neuroendocrine tumors (NETs) or other NETs where the primary site is situated in organs above the diaphragm (e.g., laryngeal and pharyngeal NETs)

PATIENT CHARACTERISTICS:

  • ECOG performance status 0-2
  • Life expectancy ≥ 12 weeks
  • Hemoglobin ≥ 10 g/dL
  • Platelet count ≥ 100,000/mm³
  • WBC ≥ 3,000/mm³
  • ANC ≥ 1,500/mm³
  • Bilirubin ≤ 2 times upper limit of normal (ULN)
  • Alkaline phosphatase ≤ 5 times ULN
  • AST and ALT ≤ 5 times ULN
  • GFR ≥ 60 mL/min
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception during and for 3 months after completion of study therapy
  • No other serious or uncontrolled illness that would preclude study participation
  • No medical or psychiatric condition that would influence the ability to provide consent

PRIOR CONCURRENT THERAPY:

  • At least 3 weeks since prior interferon therapy
  • No prior systemic chemotherapy or chemotherapy administered as part of a chemo-embolization regimen, or for this condition
  • No receptor-targeted radiolabeled therapy within the past 6 months
  • No investigational agent within the past 4 weeks
  • Prior and concurrent somatostatin analogues allowed provided symptoms are no longer controlled by this treatment or there is documented measurable disease progression on serial CT scans performed up to 6 months apart
  • No palliative radiotherapy involving lesions used to measure disease

    • Palliative radiotherapy to regions not involved in measurement of disease allowed
  • No other concurrent chemotherapy for this condition
Gender Both
Ages 18 Years and older
Accepts Healthy Volunteers No
Contacts ††
Location Countries  United Kingdom
Administrative Information Fields
NCT ID  NCT00602082
Organization ID CDR0000582315
Secondary IDs †† CRCA-CCTC-NET-01, EUDRACT-2004-005202-71, EU-207102, ISRCTN35124268
Study Sponsor  Cambridge University Hospitals NHS Foundation Trust
Collaborators ††
Investigators 
Investigator:     Pippa Corrie, PhD, FRCP     Cambridge University Hospitals NHS Foundation Trust    
Investigator:     Tim Meyer, MD, BSc, MRCP, PhD     UCL Cancer Institute    
Information Provided By National Cancer Institute (NCI)
Verification Date April 2008
First Received Date  January 25, 2008
Last Updated Date October 8, 2008

 †    Required WHO trial registration data element.
††   WHO trial registration data element that is required only if it exists.




Links to all studies - primarily for crawlers